Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31070212 | 0.91 | CTRB1 (0.48) | PNMTNPC1RAB9ACTRB1CASP1 | |
| SCHEMBL27853148 | 0.90 | PNMT (0.40) | PNMTNPC1RAB9ACTRB1HTR7 | |
| SCHEMBL2549264 | 0.87 | PNMT (0.43) | PNMTNPC1RAB9AEPHX1CASP1 | |
| SCHEMBL2549268 | 0.87 | PNMT (0.43) | PNMTNPC1RAB9AEPHX1CASP1 | |
| SCHEMBL29897120 | 0.86 | PNMT (0.42) | PNMTNPC1RAB9AEPHX1CASP1 | |
| SCHEMBL6502789 | 0.86 | PNMT (0.54) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL30079659 | 0.85 | PNMT (0.41) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL31633620 | 0.84 | PNMT (0.53) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL28291422 | 0.83 | CASP1 (0.43) | CASP1 | |
| SCHEMBL5689687 | 0.83 | PNMT (0.44) | PNMTNPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050201973-A1 | Therapeutic supramolecules | VIRTANEN JORMA (US) | 2005-09-15 | — | — | US | disclosed |
| US-6814964-B2 | BINDING EFFECTOR MOLECULE (E.G., CD4 PROTEIN) AND THERAPEUTIC EFFECTOR MOLECULE (PARTICULARLY AN ENZYME) ATTACHED TO THE SURFACE OF A LIPOSOME; FOR GENETICALLY MODIFYING A CELL; MAY ALSO CONTAIN A PROPHOSPHOLIPASE | NAGAOKA & CO. LTD. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20030104045-A1 | Novel therapeutic binding molecule complexes | BURSTEIN TECHNOLOGIES, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6379699-B1 | Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety | BURSTEIN TECHNOLOGIES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-5997861-A | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin | BURSTEIN LABORATORIES, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0789715-A4 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LAB INC (US) | 1999-08-18 | — | — | EP | disclosed |
| US-5718915-A | DRUG DELIVERY | BURSTEIN LABORATORIES, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0789715-A1 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LABORATORIES, INC. (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996032841-A9 | NOVEL THERAPEUTIC BINDING MOLECULE COMPLEXES | — | 1996-12-27 | — | — | WO | disclosed |
| WO-1996032841-A1 | NOVEL THERAPEUTIC BINDING MOLECULE COMPLEXES | BURSTEIN LABORATORIES, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996013522-A9 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | — | 1996-09-12 | — | — | WO | disclosed |
| WO-1996013522-A1 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LABORATORIES, INC. (US) | 1996-05-09 | — | — | WO | disclosed |